Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Epidermal Growth Factor Receptor Mutations”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00411047
What this trial is testing

Gefitinib in Treating Patients With Previously Untreated Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Who this might be right for
Lung Cancer
Massachusetts General Hospital 34
Testing effectiveness (Phase 2)Looking for participantsNCT06192849
What this trial is testing

To Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy

Who this might be right for
Non Small Cell Lung CancerEGFR Exon 20 Insertion Mutation
Juan LI, MD 20
Testing effectiveness (Phase 2)Study completedNCT04426825
What this trial is testing

Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Hoffmann-La Roche 23
Not applicableStudy completedNCT06595498
What this trial is testing

Next Generation Sequencing Method for the Detection of EGFR Gene Mutations in the Plasma of Patients With Lung Cancer

Who this might be right for
Carcinoma, Non-small Cell Lung Cancer (NSCLC)
Istituto Oncologico Veneto IRCCS 130
Testing effectiveness (Phase 2)UnknownNCT05165355
What this trial is testing

Adjuvant Targeted-therapy for Patients With Resected High-risk EGFR-mutant Stage IB-IIA Non-small Cell Lung Carcinoma

Who this might be right for
NSCLCEGF-R Positive Non-Small Cell Lung Cancer
Tongji University 90
Testing effectiveness (Phase 2)UnknownNCT03396185
What this trial is testing

Icotinib as Consolidation Therapy After Chemoradiotherapy in EGFR-Mutant Stage IIIA-IIIB Non-small Cell Lung Cancer

Who this might be right for
EGFR Gene MutationNon Small Cell Lung Cancer Stage IIIANon Small Cell Lung Cancer Stage IIIB
Betta Pharmaceuticals Co., Ltd. 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT04619004
What this trial is testing

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer MetastaticNon-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
Daiichi Sankyo 277
Not applicableUnknownNCT06095934
What this trial is testing

Efficacy and Safety of Neoantigen Peptide Vaccine in the Treatment of Advanced NSCLC Progressed After EGFR-TKI Treatment

Who this might be right for
NSCLCEGFR Gene Mutation
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School 20
Large-scale testing (Phase 3)Ended earlyNCT04427072
What this trial is testing

Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Novartis Pharmaceuticals 22
Not applicableStudy completedNCT00899756
What this trial is testing

Epidermal Growth Factor Receptor Mutations in the Blood of Patients With Advanced Non-Small Cell Lung Cancer

Who this might be right for
Lung Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 50
Large-scale testing (Phase 3)UnknownNCT03008109
What this trial is testing

Endostar Plus EGFR-TKI（Epidermal Growth Factor Receptor-Tyrosine-Kinase Inhibitor） as a Treatment of EGFR Mutation-positive NSCLC

Who this might be right for
Advanced CancerLung Cancer, Nonsmall Cell
Zaiwen Fan 80
Not applicableNot Yet RecruitingNCT07697716
What this trial is testing

In Vitro NSCLC EGFR-Mutant Models for Drug Sensitivity Testing

Who this might be right for
Carcinoma, Non-Small-Cell LungEGFR Gene Mutation
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 30
Testing effectiveness (Phase 2)Study completedNCT03602079
What this trial is testing

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Who this might be right for
HER2-positive Breast CancerHER2 Gene MutationHER-2 Gene Amplification+41 more
Klus Pharma Inc. 49
Post-approval studies (Phase 4)Study completedNCT02514174
What this trial is testing

Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older

Who this might be right for
Carcinoma, Non-Small-Cell LungErbB Receptors
Boehringer Ingelheim 25
Large-scale testing (Phase 3)Study completedNCT01024413
What this trial is testing

Phase III Trial to Evaluate the Elortinib vs Gefitinib in Advanced NSCLC With EGFR Exon 19 or 21 Mutations

Who this might be right for
Thoracic Neoplasms
Chinese Society of Lung Cancer 256
Testing effectiveness (Phase 2)UnknownNCT03050437
What this trial is testing

A Study Comparing Pemetrexed Plus Cisplatin Versus Pemetrexed Alone in NSCLC Patients Who Have Progressed on First Line EGFR-TKI

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Samsung Medical Center 96
Testing effectiveness (Phase 2)Looking for participantsNCT06296745
What this trial is testing

Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib.

Who this might be right for
Leptomeningeal Metastasis
Guangzhou Medical University 36
Testing effectiveness (Phase 2)UnknownNCT02960607
What this trial is testing

High-dose Icotinib Treatment Beyond Progression in EGFR Mutant NSCLC

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Chinese Academy of Medical Sciences 25
Early research (Phase 1)UnknownNCT06362980
What this trial is testing

A Study With BPI-1178 and Osimertinib in Advanced Non-small Cell Lung Cancer Patients With EGFR Mutations

Who this might be right for
NSCLC
National Cancer Center, China 20
Early research (Phase 1)Study completedNCT03452150
What this trial is testing

D-0316 First Time in Patients Ascending Dose Study

Who this might be right for
Advanced Non Small Cell Lung Cancer
InventisBio Co., Ltd 84
Next Page